YUTREPIA Dominates Inhaled Treprostinil Market | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20065524

Show notes

Liquidia’s YUTREPIA is exploding onto the scene, hitting 5,900 unique patient prescriptions and 5,000 patient starts in its first year—capturing nearly 30% of the inhaled treprostinil market. More than just numbers, it’s transforming patient lives with superior tolerability that enables higher doses and better outcomes. Outpacing a 6% market growth, YUTREPIA isn’t just slicing the pie—it’s expanding it. Doctors are already prescribing for multiple patients, betting big on its efficacy. Built on decades of patient-centric insight, the product’s focus on ease of use and real-world impact is driving rapid adoption. Looking ahead, Liquidia’s next big move is L606, a twice-daily formulation showing promise for even greater tolerability and reduced cough—with 10 clinical studies in the pipeline. Financially, YUTREPIA sales tripled in three quarters, turning the company from a net loser to a profitable powerhouse, backed by $280M in cash to fuel growth, innovation, and market dominance. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/11eeb78115ec9708

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.